A.淋巴結(jié)活檢發(fā)現(xiàn)鏡影(RS)細(xì)胞
B.顱骨蟲蝕樣缺損伴皮膚濕疹樣皮疹
C.縱隔增寬,淋巴結(jié)腫大
D.常有肝脾腫大和發(fā)熱
E.潮熱、汗多、尿VMA顯著增高
您可能感興趣的試卷
你可能感興趣的試題
A.淋巴結(jié)活檢發(fā)現(xiàn)鏡影(RS)細(xì)胞
B.顱骨蟲蝕樣缺損伴皮膚濕疹樣皮疹
C.縱隔增寬,淋巴結(jié)腫大
D.常有肝脾腫大和發(fā)熱
E.潮熱、汗多、尿VMA顯著增高
A.RBC4.0×1012/L,Hb75g/L,MCV63fl,MCH22pg,MCHC0.25,網(wǎng)織紅細(xì)胞0.010
B.RBC2.3×1012/L,Hb85g/L,MCV94fl,MCH35pg,MCHC0.35,網(wǎng)織紅細(xì)胞0.015
C.RBC2.0×1012/L,Hb60g/L,MCV84fl,MCH30pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.003
D.RBC4.5×1012/L,Hb115g/L,MCV83fl,MCH31pg,MCHC0.34,網(wǎng)織紅細(xì)胞0.015
E.RBC2.2×1012/L,Hb63g/L,MCV81fl,MCH32pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.09
A.RBC4.0×1012/L,Hb75g/L,MCV63fl,MCH22pg,MCHC0.25,網(wǎng)織紅細(xì)胞0.010
B.RBC2.3×1012/L,Hb85g/L,MCV94fl,MCH35pg,MCHC0.35,網(wǎng)織紅細(xì)胞0.015
C.RBC2.0×1012/L,Hb60g/L,MCV84fl,MCH30pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.003
D.RBC4.5×1012/L,Hb115g/L,MCV83fl,MCH31pg,MCHC0.34,網(wǎng)織紅細(xì)胞0.015
E.RBC2.2×1012/L,Hb63g/L,MCV81fl,MCH32pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.09
A.RBC4.0×1012/L,Hb75g/L,MCV63fl,MCH22pg,MCHC0.25,網(wǎng)織紅細(xì)胞0.010
B.RBC2.3×1012/L,Hb85g/L,MCV94fl,MCH35pg,MCHC0.35,網(wǎng)織紅細(xì)胞0.015
C.RBC2.0×1012/L,Hb60g/L,MCV84fl,MCH30pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.003
D.RBC4.5×1012/L,Hb115g/L,MCV83fl,MCH31pg,MCHC0.34,網(wǎng)織紅細(xì)胞0.015
E.RBC2.2×1012/L,Hb63g/L,MCV81fl,MCH32pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.09
A.RBC4.0×1012/L,Hb75g/L,MCV63fl,MCH22pg,MCHC0.25,網(wǎng)織紅細(xì)胞0.010
B.RBC2.3×1012/L,Hb85g/L,MCV94fl,MCH35pg,MCHC0.35,網(wǎng)織紅細(xì)胞0.015
C.RBC2.0×1012/L,Hb60g/L,MCV84fl,MCH30pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.003
D.RBC4.5×1012/L,Hb115g/L,MCV83fl,MCH31pg,MCHC0.34,網(wǎng)織紅細(xì)胞0.015
E.RBC2.2×1012/L,Hb63g/L,MCV81fl,MCH32pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.09
最新試題
目前非霍奇金淋巴瘤的治療主要是()
關(guān)于家族性噬血細(xì)胞綜合征的預(yù)后正確的是()
對(duì)兒童急性淋巴細(xì)胞白血病長(zhǎng)期無病生存影響最重要的藥物是()
下列有關(guān)自身免疫性溶血性貧血的描述正確的是()
確診組織細(xì)胞壞死性淋巴結(jié)炎的診斷手段是()
機(jī)體在缺鐵性貧血階段,其相關(guān)檢測(cè)結(jié)果中下列哪項(xiàng)是正確的()
為預(yù)防早產(chǎn)兒或低體重兒發(fā)生缺鐵性貧血,建議生后何時(shí)給予鐵劑()
下述哪一項(xiàng)是組織細(xì)胞壞死性淋巴結(jié)炎的病理改變特征()
診斷慢性ITP的主要根據(jù)為有ITP表現(xiàn)且病程超過()
兒童白血病治療初期口服別嘌呤醇的目的是()